What is EyePromise?
EyePromise operates at the intersection of nutritional science and preventative eye care, offering a comprehensive suite of vitamins designed to support long-term vision health. The company distinguishes itself through a rigorous, evidence-based approach, catering to a diverse demographic that includes professional athletes, aging populations, and individuals managing occasional dry eye symptoms. By fostering deep collaborations with eye care professionals and securing endorsements from high-performance athletes, EyePromise has successfully positioned its brand as a premium, efficacy-driven leader in the vision wellness market. Their business model relies on the synthesis of high-quality ingredients and professional validation to drive market penetration.
How much funding has EyePromise raised?
EyePromise has raised a total of $3.4M across 2 funding rounds:
Private Equity
$3M
Debt
$350K
Private Equity (2014): $3M with participation from DSM Venturing
Debt (2020): $350K led by PPP
Key Investors in EyePromise
DSM Venturing
Royal DSM is a global science-based company active in Nutrition, Health and Sustainable Living, focusing on high-impact investments in the life sciences sector.
PPP
Public-Private Partnership
What's next for EyePromise?
With the recent infusion of capital, EyePromise is well-positioned to accelerate its enterprise-level expansion and deepen its research initiatives. The strategic focus will likely shift toward optimizing supply chain efficiencies and broadening distribution channels to reach a wider global audience. As the company navigates its current lifecycle stage, the emphasis remains on maintaining the integrity of its scientific formulations while scaling operations to meet the rising demand for specialized nutritional support. Future growth will be predicated on the company's ability to translate clinical efficacy into sustained consumer loyalty and expanded market share within the broader health and wellness ecosystem.
See full EyePromise company page
